Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of PTG-300 in transfusion-dependent and non-transfusion-dependent beta-thalassemia
2018-004423-36Phase 2Completed
- Sponsor
- Protagonist Therapeutics, Inc.
- Start
- Mar 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of rusfertide in beta thalassemia (2 cohorts), sponsored by Protagonist Therapeutics, Inc. Primary endpoint: Long-term safety and tolerability of PTG-300. Started Mar 2019; status: completed.
02
Drugs
rusfertide
03
Conditions
beta thalassemia
Beyond the preview
Go deeper on 2018-004423-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004423-36.